• Second Genome Doses First Patient in SGM-1019 Study americanpharmaceuticalreview
    January 24, 2019
    Second Genome announced the first patient has been dosed in a Phase 2 clinical trial evaluating SGM-1019 for the treatment of nonalcoholic steatohepatitis (NASH). SGM-1019 is a first-in-class....
PharmaSources Customer Service